CD274 and Schwartz-Jampel syndrome: However, literature reports indicate that factors including ipilimumab combination showed no significant risk among 67 patients with SJS/TEN treated with PD-1/PD-L1 inhibitors.4 The discrepancy in conclusions could potentially be attributed to differences in patient populations, sample sizes, and specific treatment regimens employed in the studies.